{"ticker": {"uuid": "9fddc048-1bb8-4f7e-b0fb-edad1fcbbd71", "symbol": "CRVO", "name": "CervoMed Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "CervoMed (NASDAQ: CRVO) seeks $10M via 2.5M-share offering; patent allowance noted", "summary": "CervoMed (NASDAQ: CRVO) is initiating a public offering of 2.5 million shares of common stock at $4.00 per share, aiming to raise approximately $9.1 million in net proceeds. H.C. Wainwright & Co. will serve as the exclusive placement agent for this best-efforts offering. This fin", "url": "https://www.stocktitan.net/sec-filings/CRVO/424b5-cervo-med-inc-prospectus-supplement-debt-securities-97f945b32b6f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:40:52", "published_display": "22 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Announces $10 Million Registered Direct Offering; Engages H.C. Wainwright", "summary": "CervoMed has announced a $10 million registered direct offering of 2,500,000 common shares at $4.00 per share, with closing expected around June 22, 2026. The company engaged H.C. Wainwright & Co. as its exclusive placement agent, agreeing to various fees and issuing placement ag", "url": "https://www.tradingview.com/news/tradingview:c4781a1889743:0-cervomed-announces-10-million-registered-direct-offering-engages-h-c-wainwright/", "source_name": "TradingView", "published_at": "2026-06-22T09:40:52", "published_display": "22 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed shares surge after securing US patent protection for dementia therapy (CRVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPX1IxVjU3bUcyUC0zdFRkbVRoeXc0c0hsWFBQRGMtSkdRZHltZG5rb3c4dUJKRmxVbHJyYlFGdHY4cU5FTWVNS2JLYWUyM0ZpcDNBNlByeWo1NWE5ck9vTHdhZUxaci1xaWhhVVNFeFdjSThTdG5YcnBQZlZqQUhzeF9PblBhYS1fOWxWSmhGT2dZZTBBTk1OLS1jN2dFbm44UFI3OHF4aHlLcVBmODVuWnd1OFBzaVBfekx3YzRhMEhhdWl2cUVzaGI5cjBrbFU?oc=5", "source_name": "MSN", "published_at": "2026-06-21T02:57:30+00:00", "published_display": "21 Jun 2026 02:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042", "summary": "CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent protecting the use of its drug candidate, neflamapimod, for treating \"pure DLB\" (Dementia with Lewy bodies without substantial Alzheimer\u2019s disease-like tau pathology). This patent is exp", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314054/0/en/cervomed-secures-new-u-s-patent-protecting-use-of-neflamapimod-in-pure-dementia-with-lewy-body-patients-into-2042.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T05:40:21", "published_display": "19 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed secures U.S. patent for pure DLB treatment", "summary": "CervoMed (NASDAQ:CRVO) has secured a U.S. patent for its drug candidate, neflamapimod, specifically for treating \"pure\" dementia with Lewy bodies (DLB), extending intellectual property protection through 2042. This patent focuses on patients without Alzheimer\u2019s-like tau pathology", "url": "https://grafa.com/en/news/united-states/cervomed-secures-new-us-patent-for-neflamapimod", "source_name": "grafa.com", "published_at": "2026-06-18T17:10:51", "published_display": "18 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Reports $10 Million Direct Offering of Shares", "summary": "CervoMed has announced a direct offering of 2,173,914 shares of its common stock to institutional investors at a purchase price of $4.60 per share. The offering is expected to generate approximately $10 million in gross proceeds before deductions for placement agent fees and othe", "url": "https://www.moomoo.com/news/post/71744479/cervomed-reports-10-million-direct-offering-of-shares?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-18T17:10:14", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed prices $10M registered direct offering at $4/share", "summary": "CervoMed Inc. has announced a registered direct offering to sell 2,500,000 shares of common stock at $4.00 per share, aiming to raise $10 million for working capital and general corporate purposes. This comes after a significant stock surge and recent positive developments for th", "url": "https://www.investing.com/news/company-news/cervomed-prices-10m-registered-direct-offering-at-4share-93CH-4750415", "source_name": "Investing.com", "published_at": "2026-06-18T17:01:15", "published_display": "18 Jun 2026 17:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed sells 2.5 million shares at $4.00 each to raise $10M", "summary": "CervoMed (NASDAQ: CRVO) has announced a registered direct offering of 2.5 million common shares at $4.00 each, aiming to raise $10 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is expected to close around June 22, 2026. The company plans t", "url": "https://www.stocktitan.net/news/CRVO/cervo-med-announces-10-million-registered-direct-offering-of-common-j0etvagylt9k.html", "source_name": "Stock Titan", "published_at": "2026-06-18T16:35:16", "published_display": "18 Jun 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Announces $10 Million Registered Direct Offering", "summary": "CervoMed Inc. announced a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, totaling $10 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. Procee", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314430/0/en/cervomed-announces-10-million-registered-direct-offering-of-common-stock-priced-at-the-market-under-nasdaq-rules.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:35:15", "published_display": "18 Jun 2026 16:35", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQa3o4dThpZVdGel9WTVNXbEtHUndHOGV1cndwbGNJaXB3YlU2bFhJbDBRZEVSNEswRWtfRVhCUmNxTldsNHg5ZnhRU0djMnk0dmd0UHNlcjFOLUZQT3RhMlpjQ2VLc2tHRkxnWlJ1Q1VHb1ItVWU1VndJODhjcjR2N20xbEkzUTZNajRsZXBFMEhBNndlV1Y0cA?oc=5", "source_name": "Market source", "published_at": "2026-06-18T14:08:36+00:00", "published_display": "18 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Soars As Insider Buy And Cash Raise Extend Runway", "summary": "CervoMed Inc. (CRVO) stock has surged over 56% due to optimistic sentiment surrounding its neurodegenerative pipeline, a $10.5 million private placement extending its cash runway into Q2 2027, and a significant $3 million insider purchase by Joshua S. Boger. The company has FDA a", "url": "https://stockstotrade.com/news/cervomed-inc-crvo-news-2026_06_18/", "source_name": "StocksToTrade", "published_at": "2026-06-18T14:09:15", "published_display": "18 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Stocks To Watch Today: CRVO, SPRO, QNRX", "summary": "CervoMed Inc. (CRVO) has secured a patent for its drug candidate Neflamapimod for treating dementia with Lewy bodies (DLB), extending intellectual property protection until 2042. This is significant as there are currently no approved treatments for DLB in the U.S. or E.U. The art", "url": "https://www.rttnews.com/3661253/3-stocks-to-watch-today-crvo-spro-qnrx.aspx", "source_name": "RTTNews", "published_at": "2026-06-18T13:09:16", "published_display": "18 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed stock jumps 20% on new U.S. patent allowance", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPMDZ6SEp5UGZ2M2RNREg0bEVnLS1VM0pmVTJ3aEwyUkJ0b1hVNS1xdG5fU2dXTFYyemNLRTJ1dG9IeW9rbXVYNmF5R2dPRFlFRkxyWTMtWUZVZkRNSjZlNlQ5dGdXUERqMkdGbWJOU0NBZjYtUjVlUE5YTUpRSVpJRkhfWnpVZ2Vzd0xNSUxxaWhkYXoxbWg4Z1RxZXk5RGNXbXVxbE9QX0tNbk1POW1DUUZB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T12:07:20+00:00", "published_display": "18 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed wins U.S. patent allowance for pure DLB treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaEhPelA0bF9iNmI0RlRia1hrUnl0N1AzekRPWVYwTGFfQTJ1VmtjRU9JY3RPdDh5ZUNFSExaSTlsZW9zTTIxZVFzT1VhTkQyNk5US2Zwazh4M1YzNnQ2dUlneHNMeEptX1VpOHJxd29qaV91U0hpZ2cxQXZBQUw2NXRWNkdQYjJJZ3U2djQwMFh3UFVBT3NYRDhkQlJGR21KQzlCdUpQSXoxZE1xd1Y0YTAtMDBSN2wzU2pteGpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) secures USPTO patent protection on neflamapimod to 2042", "summary": "CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent covering its drug candidate neflamapimod. This patent protects the use of neflamapimod for treating dementia with Lewy bodies in patients without substantial Alzheimer\u2019s disease-like tau", "url": "https://www.stocktitan.net/sec-filings/CRVO/8-k-cervo-med-inc-reports-material-event-d78b2eb68a9b.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) to raise $10M in registered direct stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUE5Sc00tSl9KNldxa1NJTEZBdjZZcnBFQkhnMWVoY0piYk0yTWVvQ25jWjVPX1pDd1NXUDBQYjhOUUxTUmlkTHcxSmhURnRoSVZuWlV6WGRUR2ZWQ3pWWmFnR3JodFRRcDhCbG9OMFpBWFZQM2kwSk1OVGxaYVNDbk1ULVRhQ1ZjUGNqbEd0dWZGd1hxbHhpVkJVOFcyU0RZemNsQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Stock (CRVO) Opinions on Recent Volatility Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQdGVLTUxLTXluSnJKT2VsUTlPd2xob2pHLWZnWHpHVTFVb3JXSlRQcnFLZFhrNmFtMVV4T1ZscGFYMFlScWMzZk9wUGQtS25RUGVTNFNRemxJUHl5eG03Z0djNFo1NHdabWRaem1UMlpFNkNrWFBrTUIyS2l2R3BJbDhDdS1FTi1tSE9QVXAwRXcxN2ZWUHdfSnZ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T14:03:00+00:00", "published_display": "17 Jun 2026 14:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Promising Penny Stocks To Watch In June 2026", "summary": "This article highlights three promising U.S. penny stocks for June 2026 from Simply Wall St's screener: CervoMed (CRVO), Codexis (CDXS), and Laird Superfood (LSF). Each company is analyzed for its financial health, market capitalization, recent performance, key developments, and ", "url": "https://simplywall.st/stocks/us/food-beverage-tobacco/nysemkt-lsf/laird-superfood/news/promising-penny-stocks-to-watch-in-june-2026/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-17T11:39:32", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of CervoMed Inc. \u2013 DUS:DP8", "summary": "This article provides the long-term debt to total equity ratio for CervoMed Inc. (DUS:DP8) as found on TradingView. It includes details about the company's stock exchange listing and financial data, while also listing various resources and tools available on the platform.", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-06-16T16:39:33", "published_display": "16 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$CervoMed (CRVO.US)$", "summary": "This article mentions CervoMed (CRVO.US) in the context of a discussion on the moomoo Community platform. The content is primarily disclaimers and navigation elements for the moomoo platform, indicating that CervoMed was a topic of discussion among users.", "url": "https://www.moomoo.com/community/feed/10-00-close-116760768020489?chain_id=Name1K9-3FXPhg.1l33eag&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A63%2C%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fdiscussion%2Fshare-your-profit-loss-4003%22%7D", "source_name": "Moomoo", "published_at": "2026-06-16T16:11:09", "published_display": "16 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Cash Flow \u2013 DUS:DP8", "summary": "CervoMed Inc. (DUS:DP8) reported its cash flow details, indicating a free cash flow of \u20ac-6.94 million for Q1 2026. For the full year 2025, the company recorded a free cash flow and operating cash flow of \u20ac-19.97 million each. The article provides a historical overview of the comp", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-16T14:11:10", "published_display": "16 Jun 2026 14:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Current ratio of CervoMed Inc. \u2013 DUS:DP8", "summary": "The article focuses on the current ratio of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It provides a brief financial overview within the TradingView platform, noting that market data is from ICE Data Services and reference data from FactSet. The ", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/current-ratio/", "source_name": "TradingView", "published_at": "2026-06-16T14:11:09", "published_display": "16 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Pops As CervoMed Extends Runway And Insider Buys Big", "summary": "CervoMed Inc. (CRVO) stock surged over 22% after securing a $10.5 million private placement, extending its cash runway into Q2 2027 and enabling the pursuit of a strategic partner for Phase 3 neflamapimod trials for dementia with Lewy bodies. A major insider, Joshua S. Boger, als", "url": "https://stockstotrade.com/news/cervomed-inc-crvo-news-2026_06_16/", "source_name": "StocksToTrade", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase", "summary": "CervoMed Inc. (CRVO) shares surged over 30% in premarket trading following an SEC filing that revealed a trust linked to a company director purchased approximately $3 million in units. This insider-related transaction, priced above Monday's close, comes on the heels of a $10.5 mi", "url": "https://ts2.tech/en/cervomed-shares-rise-in-early-trade-after-3-million-insider-related-purchase/", "source_name": "TechStock\u00b2", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from financing activities of CervoMed Inc. \u2013 DUS:DP8", "summary": "This article provides details on the cash generated from the financing activities of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It presents an overview of the company's financial data, though specific figures for cash from financing activities ar", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-cash-flow/cash-f-financing-activities/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Statistics \u2013 DUS:DP8", "summary": "This article provides financial statistics for CervoMed Inc. (DUS:DP8) on the TradingView platform. It details various annual and quarterly financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, while noting that much of the ", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Earnings and Revenue \u2013 DUS:DP8", "summary": "CervoMed Inc. reported an EPS of -0.74 EUR last quarter, missing the -0.68 EUR estimate. Revenue for the same period was 0.00 EUR, significantly below the estimated 61.82K EUR. Analysts forecast an EPS of -0.69 EUR and revenue of 36.98K EUR for the next quarter.", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-earnings/", "source_name": "TradingView", "published_at": "2026-06-16T13:11:10", "published_display": "16 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed stock surges 32% after director buys shares", "summary": "CervoMed Inc. (NASDAQ:CRVO) stock surged 32.3% in premarket trading after director Joshua Boger, through the Joshua S. Boger 2021 Trust, purchased 955,414 shares as part of a private placement. The transaction involved common stock, Series B warrants with an exercise price of $3.", "url": "https://www.investing.com/news/stock-market-news/cervomed-stock-surges-32-after-director-buys-shares-93CH-4744987", "source_name": "Investing.com", "published_at": "2026-06-16T13:11:09", "published_display": "16 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Draws Traders As Insider Buying Follows Financing Deal", "summary": "CervoMed Inc. (CRVO) stock is trending up following promising Alzheimer\u2019s trial progress and a $10.5 million private placement extending its cash runway. Key insider Joshua S. Boger's purchase of 955,414 shares for $3 million signals strong conviction, despite the dilutive nature", "url": "https://www.timothysykes.com/news/cervomed-inc-crvo-news-2026_06_16/", "source_name": "Timothy Sykes", "published_at": "2026-06-16T13:09:49", "published_display": "16 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings", "summary": "CervoMed Inc. announced that it has updated its investor presentation materials, which are now available on its website. These materials cover the company's business, clinical studies, development plans, and financial position, and are intended for use in meetings with investors ", "url": "https://www.stocktitan.net/sec-filings/CRVO/8-k-cervo-med-inc-reports-material-event-9a9537ac0fac.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:08:58", "published_display": "16 Jun 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com", "summary": "CervoMed director Joshua Boger acquired common stock valued at nearly $3 million on June 11, 2026, as part of a private placement. This transaction increased his indirect holdings to 1,795,865 shares through trusts, in addition to his direct holdings. The company recently complet", "url": "https://m.in.investing.com/news/insider-trading-news/cervomed-director-joshua-boger-acquires-299m-in-common-stock-93CH-5455927?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-16T04:08:58", "published_display": "16 Jun 2026 04:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake", "summary": "Joshua S. Boger has filed an Amendment No. 2 to his Schedule 13D for CervoMed Inc. (CRVO), disclosing beneficial ownership of 2,204,143 shares, representing 19.99% of the outstanding common stock. This ownership includes direct holdings, shares held in trusts, stock options, and ", "url": "https://www.stocktitan.net/sec-filings/CRVO/schedule-13d-a-cervo-med-inc-amended-major-shareholder-report-1a0f65442822.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:08:58", "published_display": "16 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Files Form 8-K with SEC \u2013 Company Information, Address, and Common Stock Details", "summary": "CervoMed Inc. has filed an 8-K form with the SEC on June 15, 2026, providing routine updates under Regulation FD, which ensures simultaneous access to material information for all investors. The filing includes details about the company's address, stock symbol (CRVO on NASDAQ), a", "url": "https://www.minichart.com.sg/2026/06/16/cervomed-inc-files-form-8-k-with-sec-company-information-address-and-common-stock-details/", "source_name": "Minichart", "published_at": "2026-06-16T02:08:58", "published_display": "16 Jun 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRmFqZExZNFg2R05rdGlkRS1wdkhBcmN0S3hFTTRvc2lzMnJVVFVmQnFfank0Z3pEUkxmYTlYeU02b3ZEX21VdEdNSmF3WWdHcS1pNHpLYzlCVDlrMDZ5VEhLdHpuZmZLYUNLLVpBTWdIa0ZQOG8tNzRpZDUtcWdmdlc4OTdFVlpHbzhUNFdfVkJBT0l3S0QtaXZNbnpRalpUSGZEM0JUYUI3blk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T21:37:36+00:00", "published_display": "15 Jun 2026 21:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Insiders Lose Out As Stock Sinks To US$2.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMUp2ck1HQ1hhSmw3TDN6NkRsZGJUakN4QUZSckY5WUJNQ2o4a2FkUWdUSlpKZmJkUFpWNlNtLWw4cXM0cVBtWDkxV2ZvNG1iZW1Ya2VtaTd0dWVPa3JKUG4xck9YVWtOUUJiMWR5b09iSHEyQkNvYTlRbnhqY2kzWHZGZDB3X2Q2ZVlGVmVjYzN3YS1WNC1qc0FnZldPWDJw?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) awards 8,150 stock options to new board director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcV9iTWJvNWZrV180aTF6VklXbl93YlY2TXpURWFXM2ZkQ2MtVzJKWjNvUE9mZGxOUG42M0Z6OTNncVNkeXhMN05oR2ZoazN1czhGMU9ucHJtaHlWWTBRNW1TUXAxQjF4OVhyLTFqMGNKT3NZaEFhY2cxYllJeHc3TzhYdHlKS29SN093UERoSFo1LUQ1b2xYUnA4STJheVdJa0JRTjNxSHNJMTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) director and CEO\u2019s spouse granted 8,150 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNOFpNQ1JKS0FYN210UExkSkJPRFhxQ2dnRG0tV1lFd256SklDMjZFeVZtTElYZUs2Ry14Ynk2MDhTS1pWTmdMb1U4YUxReG1aWHF4bWRXYjBUUzlFNGw1b21QTTJubkVPYWkzQmVNdi1FN3doLXJRY0toTjhQSElDUERzOV9sbnBKano0c1lsLW1aelhBSm1XVXdKRTVKYTBqOGtoOTRibG5BdE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] CervoMed Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPLVVZNjZwREtsRmRVZGM4bWtxR0dsc1lqTWhoMDBlaXRITnY5UmNDaUV5bllzd25ORXJ6ZldyT3UzTUkzclZJclZpTkJkRVZVVFBNaHFWZkI4THFuOXdkeGp2SFotSXlhcGJSMVg4MTVFNFcwcWVPX0dXYVpQR29VbldaMThwOVg3d251dWx2M3BqVGhiOERwUEhjSFdoaTBHVmJnWXVXVFF3c2M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) secures $10.5M financing to extend cash runway into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUHE5bkNlSDVuQzNwV0ZjTVBDVGZWUXJrREdsanBDV3oxZDZVVUN0UTg0TjlTNDFkQlczSGZFT3FVOHcwdEpFUURaLTJaMkRuNFd2bmpNR1ZPYXYtUkgwQUh2cXpxWWxPd0lWN3Z6dXBQVC1hS1FUeHBoR2tLZWxScDV6WlY3cllrQWpiclFJeDBHdzI1M1M1OG1oRjRhUGdFNG1sVg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dementia drug push: CervoMed\u2019s $10.5M fuels Lewy body trial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPR1FkeERsNWtFMnpwYkZnN3p2V3JHSWZCZks4UDdkTFBPUzZkVWVSd3lhU0xHRHZrdEtEYkFnOW9xb21BQ1BTTmYxb1JnSGdtbEg4Um5yMDJaWUQ5RjBzMXlnbHhseWF1X29tR2NSS1RXWEFLbXdxNEV4RENZTHd6MUtvdXAza01XWWZWYlZpOUFSc2ZHVkQteU9NTklWNXdYRUFfM1JuZC1RQng2Vjl0VVJpTnp2d0llcEg2azRKZjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lewy body dementia MRI data spotlight CervoMed's planned Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNN1ZkM3JKaUVGN2xSOGwwbDN3cEVrbXBzTmdNVDhIWW1uT2VzaW0tQUpmRjlHVDd4MEdDdGdfZ1d0ZVYwTy16Ykt0WENJTjJBcW91ZV9XS1hTcGFtYkxNam1ld0hPUFVTenlnalNLb2RHbHdfbU1wMkdMQnJPaVNzakpqOW42STlmdWpzbGM1Zi1weTdXLXI4U0psUVBYaDcxNUNPU0dFeEtoSV9iTHJKd2VPMDNncWw5Tzg2OEQwNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With no approved DLB drugs, CervoMed maps out a Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdU5fUkotY0xHUXgwSHNla2RoQm5aMlF4UEwwMi14Yks0NS1TWlVmQzRvSUZkWnVaTmkyNy15cFdmczVNdWN6TzRBV0UxY3Z3WkFPZWF5VVg4dE9pS2dzcW1wLVk3ZjF4cW5RSktBV29CalFaVHdYcGp0OGdOVGh2aWNJVG5KczdEZnY1clFmMXVsU1A1aGlpYV90WndlS0lTc2VaVy13RVhWdi15OWplTmRVc3NfaXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "CervoMed (NASDAQ: CRVO) seeks $10M via 2.5M-share offering; patent allowance noted", "summary": "CervoMed (NASDAQ: CRVO) is initiating a public offering of 2.5 million shares of common stock at $4.00 per share, aiming to raise approximately $9.1 million in net proceeds. H.C. Wainwright & Co. will serve as the exclusive placement agent for this best-efforts offering. This fin", "url": "https://www.stocktitan.net/sec-filings/CRVO/424b5-cervo-med-inc-prospectus-supplement-debt-securities-97f945b32b6f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:40:52", "published_display": "22 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Announces $10 Million Registered Direct Offering; Engages H.C. Wainwright", "summary": "CervoMed has announced a $10 million registered direct offering of 2,500,000 common shares at $4.00 per share, with closing expected around June 22, 2026. The company engaged H.C. Wainwright & Co. as its exclusive placement agent, agreeing to various fees and issuing placement ag", "url": "https://www.tradingview.com/news/tradingview:c4781a1889743:0-cervomed-announces-10-million-registered-direct-offering-engages-h-c-wainwright/", "source_name": "TradingView", "published_at": "2026-06-22T09:40:52", "published_display": "22 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed shares surge after securing US patent protection for dementia therapy (CRVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPX1IxVjU3bUcyUC0zdFRkbVRoeXc0c0hsWFBQRGMtSkdRZHltZG5rb3c4dUJKRmxVbHJyYlFGdHY4cU5FTWVNS2JLYWUyM0ZpcDNBNlByeWo1NWE5ck9vTHdhZUxaci1xaWhhVVNFeFdjSThTdG5YcnBQZlZqQUhzeF9PblBhYS1fOWxWSmhGT2dZZTBBTk1OLS1jN2dFbm44UFI3OHF4aHlLcVBmODVuWnd1OFBzaVBfekx3YzRhMEhhdWl2cUVzaGI5cjBrbFU?oc=5", "source_name": "MSN", "published_at": "2026-06-21T02:57:30+00:00", "published_display": "21 Jun 2026 02:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042", "summary": "CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent protecting the use of its drug candidate, neflamapimod, for treating \"pure DLB\" (Dementia with Lewy bodies without substantial Alzheimer\u2019s disease-like tau pathology). This patent is exp", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314054/0/en/cervomed-secures-new-u-s-patent-protecting-use-of-neflamapimod-in-pure-dementia-with-lewy-body-patients-into-2042.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T05:40:21", "published_display": "19 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed secures U.S. patent for pure DLB treatment", "summary": "CervoMed (NASDAQ:CRVO) has secured a U.S. patent for its drug candidate, neflamapimod, specifically for treating \"pure\" dementia with Lewy bodies (DLB), extending intellectual property protection through 2042. This patent focuses on patients without Alzheimer\u2019s-like tau pathology", "url": "https://grafa.com/en/news/united-states/cervomed-secures-new-us-patent-for-neflamapimod", "source_name": "grafa.com", "published_at": "2026-06-18T17:10:51", "published_display": "18 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Reports $10 Million Direct Offering of Shares", "summary": "CervoMed has announced a direct offering of 2,173,914 shares of its common stock to institutional investors at a purchase price of $4.60 per share. The offering is expected to generate approximately $10 million in gross proceeds before deductions for placement agent fees and othe", "url": "https://www.moomoo.com/news/post/71744479/cervomed-reports-10-million-direct-offering-of-shares?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-18T17:10:14", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed prices $10M registered direct offering at $4/share", "summary": "CervoMed Inc. has announced a registered direct offering to sell 2,500,000 shares of common stock at $4.00 per share, aiming to raise $10 million for working capital and general corporate purposes. This comes after a significant stock surge and recent positive developments for th", "url": "https://www.investing.com/news/company-news/cervomed-prices-10m-registered-direct-offering-at-4share-93CH-4750415", "source_name": "Investing.com", "published_at": "2026-06-18T17:01:15", "published_display": "18 Jun 2026 17:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed sells 2.5 million shares at $4.00 each to raise $10M", "summary": "CervoMed (NASDAQ: CRVO) has announced a registered direct offering of 2.5 million common shares at $4.00 each, aiming to raise $10 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is expected to close around June 22, 2026. The company plans t", "url": "https://www.stocktitan.net/news/CRVO/cervo-med-announces-10-million-registered-direct-offering-of-common-j0etvagylt9k.html", "source_name": "Stock Titan", "published_at": "2026-06-18T16:35:16", "published_display": "18 Jun 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Announces $10 Million Registered Direct Offering", "summary": "CervoMed Inc. announced a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, totaling $10 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. Procee", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314430/0/en/cervomed-announces-10-million-registered-direct-offering-of-common-stock-priced-at-the-market-under-nasdaq-rules.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:35:15", "published_display": "18 Jun 2026 16:35", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQa3o4dThpZVdGel9WTVNXbEtHUndHOGV1cndwbGNJaXB3YlU2bFhJbDBRZEVSNEswRWtfRVhCUmNxTldsNHg5ZnhRU0djMnk0dmd0UHNlcjFOLUZQT3RhMlpjQ2VLc2tHRkxnWlJ1Q1VHb1ItVWU1VndJODhjcjR2N20xbEkzUTZNajRsZXBFMEhBNndlV1Y0cA?oc=5", "source_name": "Market source", "published_at": "2026-06-18T14:08:36+00:00", "published_display": "18 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Soars As Insider Buy And Cash Raise Extend Runway", "summary": "CervoMed Inc. (CRVO) stock has surged over 56% due to optimistic sentiment surrounding its neurodegenerative pipeline, a $10.5 million private placement extending its cash runway into Q2 2027, and a significant $3 million insider purchase by Joshua S. Boger. The company has FDA a", "url": "https://stockstotrade.com/news/cervomed-inc-crvo-news-2026_06_18/", "source_name": "StocksToTrade", "published_at": "2026-06-18T14:09:15", "published_display": "18 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Stocks To Watch Today: CRVO, SPRO, QNRX", "summary": "CervoMed Inc. (CRVO) has secured a patent for its drug candidate Neflamapimod for treating dementia with Lewy bodies (DLB), extending intellectual property protection until 2042. This is significant as there are currently no approved treatments for DLB in the U.S. or E.U. The art", "url": "https://www.rttnews.com/3661253/3-stocks-to-watch-today-crvo-spro-qnrx.aspx", "source_name": "RTTNews", "published_at": "2026-06-18T13:09:16", "published_display": "18 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed stock jumps 20% on new U.S. patent allowance", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPMDZ6SEp5UGZ2M2RNREg0bEVnLS1VM0pmVTJ3aEwyUkJ0b1hVNS1xdG5fU2dXTFYyemNLRTJ1dG9IeW9rbXVYNmF5R2dPRFlFRkxyWTMtWUZVZkRNSjZlNlQ5dGdXUERqMkdGbWJOU0NBZjYtUjVlUE5YTUpRSVpJRkhfWnpVZ2Vzd0xNSUxxaWhkYXoxbWg4Z1RxZXk5RGNXbXVxbE9QX0tNbk1POW1DUUZB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T12:07:20+00:00", "published_display": "18 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed wins U.S. patent allowance for pure DLB treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaEhPelA0bF9iNmI0RlRia1hrUnl0N1AzekRPWVYwTGFfQTJ1VmtjRU9JY3RPdDh5ZUNFSExaSTlsZW9zTTIxZVFzT1VhTkQyNk5US2Zwazh4M1YzNnQ2dUlneHNMeEptX1VpOHJxd29qaV91U0hpZ2cxQXZBQUw2NXRWNkdQYjJJZ3U2djQwMFh3UFVBT3NYRDhkQlJGR21KQzlCdUpQSXoxZE1xd1Y0YTAtMDBSN2wzU2pteGpB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) secures USPTO patent protection on neflamapimod to 2042", "summary": "CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent covering its drug candidate neflamapimod. This patent protects the use of neflamapimod for treating dementia with Lewy bodies in patients without substantial Alzheimer\u2019s disease-like tau", "url": "https://www.stocktitan.net/sec-filings/CRVO/8-k-cervo-med-inc-reports-material-event-d78b2eb68a9b.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:09:15", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) to raise $10M in registered direct stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUE5Sc00tSl9KNldxa1NJTEZBdjZZcnBFQkhnMWVoY0piYk0yTWVvQ25jWjVPX1pDd1NXUDBQYjhOUUxTUmlkTHcxSmhURnRoSVZuWlV6WGRUR2ZWQ3pWWmFnR3JodFRRcDhCbG9OMFpBWFZQM2kwSk1OVGxaYVNDbk1ULVRhQ1ZjUGNqbEd0dWZGd1hxbHhpVkJVOFcyU0RZemNsQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Stock (CRVO) Opinions on Recent Volatility Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQdGVLTUxLTXluSnJKT2VsUTlPd2xob2pHLWZnWHpHVTFVb3JXSlRQcnFLZFhrNmFtMVV4T1ZscGFYMFlScWMzZk9wUGQtS25RUGVTNFNRemxJUHl5eG03Z0djNFo1NHdabWRaem1UMlpFNkNrWFBrTUIyS2l2R3BJbDhDdS1FTi1tSE9QVXAwRXcxN2ZWUHdfSnZ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T14:03:00+00:00", "published_display": "17 Jun 2026 14:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Promising Penny Stocks To Watch In June 2026", "summary": "This article highlights three promising U.S. penny stocks for June 2026 from Simply Wall St's screener: CervoMed (CRVO), Codexis (CDXS), and Laird Superfood (LSF). Each company is analyzed for its financial health, market capitalization, recent performance, key developments, and ", "url": "https://simplywall.st/stocks/us/food-beverage-tobacco/nysemkt-lsf/laird-superfood/news/promising-penny-stocks-to-watch-in-june-2026/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-17T11:39:32", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of CervoMed Inc. \u2013 DUS:DP8", "summary": "This article provides the long-term debt to total equity ratio for CervoMed Inc. (DUS:DP8) as found on TradingView. It includes details about the company's stock exchange listing and financial data, while also listing various resources and tools available on the platform.", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-06-16T16:39:33", "published_display": "16 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$CervoMed (CRVO.US)$", "summary": "This article mentions CervoMed (CRVO.US) in the context of a discussion on the moomoo Community platform. The content is primarily disclaimers and navigation elements for the moomoo platform, indicating that CervoMed was a topic of discussion among users.", "url": "https://www.moomoo.com/community/feed/10-00-close-116760768020489?chain_id=Name1K9-3FXPhg.1l33eag&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A63%2C%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fdiscussion%2Fshare-your-profit-loss-4003%22%7D", "source_name": "Moomoo", "published_at": "2026-06-16T16:11:09", "published_display": "16 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Cash Flow \u2013 DUS:DP8", "summary": "CervoMed Inc. (DUS:DP8) reported its cash flow details, indicating a free cash flow of \u20ac-6.94 million for Q1 2026. For the full year 2025, the company recorded a free cash flow and operating cash flow of \u20ac-19.97 million each. The article provides a historical overview of the comp", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-16T14:11:10", "published_display": "16 Jun 2026 14:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Current ratio of CervoMed Inc. \u2013 DUS:DP8", "summary": "The article focuses on the current ratio of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It provides a brief financial overview within the TradingView platform, noting that market data is from ICE Data Services and reference data from FactSet. The ", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/current-ratio/", "source_name": "TradingView", "published_at": "2026-06-16T14:11:09", "published_display": "16 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Pops As CervoMed Extends Runway And Insider Buys Big", "summary": "CervoMed Inc. (CRVO) stock surged over 22% after securing a $10.5 million private placement, extending its cash runway into Q2 2027 and enabling the pursuit of a strategic partner for Phase 3 neflamapimod trials for dementia with Lewy bodies. A major insider, Joshua S. Boger, als", "url": "https://stockstotrade.com/news/cervomed-inc-crvo-news-2026_06_16/", "source_name": "StocksToTrade", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase", "summary": "CervoMed Inc. (CRVO) shares surged over 30% in premarket trading following an SEC filing that revealed a trust linked to a company director purchased approximately $3 million in units. This insider-related transaction, priced above Monday's close, comes on the heels of a $10.5 mi", "url": "https://ts2.tech/en/cervomed-shares-rise-in-early-trade-after-3-million-insider-related-purchase/", "source_name": "TechStock\u00b2", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from financing activities of CervoMed Inc. \u2013 DUS:DP8", "summary": "This article provides details on the cash generated from the financing activities of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It presents an overview of the company's financial data, though specific figures for cash from financing activities ar", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-cash-flow/cash-f-financing-activities/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Statistics \u2013 DUS:DP8", "summary": "This article provides financial statistics for CervoMed Inc. (DUS:DP8) on the TradingView platform. It details various annual and quarterly financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, while noting that much of the ", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-statistics-and-ratios/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:49", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Earnings and Revenue \u2013 DUS:DP8", "summary": "CervoMed Inc. reported an EPS of -0.74 EUR last quarter, missing the -0.68 EUR estimate. Revenue for the same period was 0.00 EUR, significantly below the estimated 61.82K EUR. Analysts forecast an EPS of -0.69 EUR and revenue of 36.98K EUR for the next quarter.", "url": "https://www.tradingview.com/symbols/DUS-DP8/financials-earnings/", "source_name": "TradingView", "published_at": "2026-06-16T13:11:10", "published_display": "16 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed stock surges 32% after director buys shares", "summary": "CervoMed Inc. (NASDAQ:CRVO) stock surged 32.3% in premarket trading after director Joshua Boger, through the Joshua S. Boger 2021 Trust, purchased 955,414 shares as part of a private placement. The transaction involved common stock, Series B warrants with an exercise price of $3.", "url": "https://www.investing.com/news/stock-market-news/cervomed-stock-surges-32-after-director-buys-shares-93CH-4744987", "source_name": "Investing.com", "published_at": "2026-06-16T13:11:09", "published_display": "16 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVO Stock Draws Traders As Insider Buying Follows Financing Deal", "summary": "CervoMed Inc. (CRVO) stock is trending up following promising Alzheimer\u2019s trial progress and a $10.5 million private placement extending its cash runway. Key insider Joshua S. Boger's purchase of 955,414 shares for $3 million signals strong conviction, despite the dilutive nature", "url": "https://www.timothysykes.com/news/cervomed-inc-crvo-news-2026_06_16/", "source_name": "Timothy Sykes", "published_at": "2026-06-16T13:09:49", "published_display": "16 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings", "summary": "CervoMed Inc. announced that it has updated its investor presentation materials, which are now available on its website. These materials cover the company's business, clinical studies, development plans, and financial position, and are intended for use in meetings with investors ", "url": "https://www.stocktitan.net/sec-filings/CRVO/8-k-cervo-med-inc-reports-material-event-9a9537ac0fac.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:08:58", "published_display": "16 Jun 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com", "summary": "CervoMed director Joshua Boger acquired common stock valued at nearly $3 million on June 11, 2026, as part of a private placement. This transaction increased his indirect holdings to 1,795,865 shares through trusts, in addition to his direct holdings. The company recently complet", "url": "https://m.in.investing.com/news/insider-trading-news/cervomed-director-joshua-boger-acquires-299m-in-common-stock-93CH-5455927?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-16T04:08:58", "published_display": "16 Jun 2026 04:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake", "summary": "Joshua S. Boger has filed an Amendment No. 2 to his Schedule 13D for CervoMed Inc. (CRVO), disclosing beneficial ownership of 2,204,143 shares, representing 19.99% of the outstanding common stock. This ownership includes direct holdings, shares held in trusts, stock options, and ", "url": "https://www.stocktitan.net/sec-filings/CRVO/schedule-13d-a-cervo-med-inc-amended-major-shareholder-report-1a0f65442822.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:08:58", "published_display": "16 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Inc. Files Form 8-K with SEC \u2013 Company Information, Address, and Common Stock Details", "summary": "CervoMed Inc. has filed an 8-K form with the SEC on June 15, 2026, providing routine updates under Regulation FD, which ensures simultaneous access to material information for all investors. The filing includes details about the company's address, stock symbol (CRVO on NASDAQ), a", "url": "https://www.minichart.com.sg/2026/06/16/cervomed-inc-files-form-8-k-with-sec-company-information-address-and-common-stock-details/", "source_name": "Minichart", "published_at": "2026-06-16T02:08:58", "published_display": "16 Jun 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRmFqZExZNFg2R05rdGlkRS1wdkhBcmN0S3hFTTRvc2lzMnJVVFVmQnFfank0Z3pEUkxmYTlYeU02b3ZEX21VdEdNSmF3WWdHcS1pNHpLYzlCVDlrMDZ5VEhLdHpuZmZLYUNLLVpBTWdIa0ZQOG8tNzRpZDUtcWdmdlc4OTdFVlpHbzhUNFdfVkJBT0l3S0QtaXZNbnpRalpUSGZEM0JUYUI3blk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T21:37:36+00:00", "published_display": "15 Jun 2026 21:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed Insiders Lose Out As Stock Sinks To US$2.45", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMUp2ck1HQ1hhSmw3TDN6NkRsZGJUakN4QUZSckY5WUJNQ2o4a2FkUWdUSlpKZmJkUFpWNlNtLWw4cXM0cVBtWDkxV2ZvNG1iZW1Ya2VtaTd0dWVPa3JKUG4xck9YVWtOUUJiMWR5b09iSHEyQkNvYTlRbnhqY2kzWHZGZDB3X2Q2ZVlGVmVjYzN3YS1WNC1qc0FnZldPWDJw?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) awards 8,150 stock options to new board director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcV9iTWJvNWZrV180aTF6VklXbl93YlY2TXpURWFXM2ZkQ2MtVzJKWjNvUE9mZGxOUG42M0Z6OTNncVNkeXhMN05oR2ZoazN1czhGMU9ucHJtaHlWWTBRNW1TUXAxQjF4OVhyLTFqMGNKT3NZaEFhY2cxYllJeHc3TzhYdHlKS29SN093UERoSFo1LUQ1b2xYUnA4STJheVdJa0JRTjNxSHNJMTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (CRVO) director and CEO\u2019s spouse granted 8,150 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNOFpNQ1JKS0FYN210UExkSkJPRFhxQ2dnRG0tV1lFd256SklDMjZFeVZtTElYZUs2Ry14Ynk2MDhTS1pWTmdMb1U4YUxReG1aWHF4bWRXYjBUUzlFNGw1b21QTTJubkVPYWkzQmVNdi1FN3doLXJRY0toTjhQSElDUERzOV9sbnBKano0c1lsLW1aelhBSm1XVXdKRTVKYTBqOGtoOTRibG5BdE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] CervoMed Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPLVVZNjZwREtsRmRVZGM4bWtxR0dsc1lqTWhoMDBlaXRITnY5UmNDaUV5bllzd25ORXJ6ZldyT3UzTUkzclZJclZpTkJkRVZVVFBNaHFWZkI4THFuOXdkeGp2SFotSXlhcGJSMVg4MTVFNFcwcWVPX0dXYVpQR29VbldaMThwOVg3d251dWx2M3BqVGhiOERwUEhjSFdoaTBHVmJnWXVXVFF3c2M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CervoMed (NASDAQ: CRVO) secures $10.5M financing to extend cash runway into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUHE5bkNlSDVuQzNwV0ZjTVBDVGZWUXJrREdsanBDV3oxZDZVVUN0UTg0TjlTNDFkQlczSGZFT3FVOHcwdEpFUURaLTJaMkRuNFd2bmpNR1ZPYXYtUkgwQUh2cXpxWWxPd0lWN3Z6dXBQVC1hS1FUeHBoR2tLZWxScDV6WlY3cllrQWpiclFJeDBHdzI1M1M1OG1oRjRhUGdFNG1sVg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dementia drug push: CervoMed\u2019s $10.5M fuels Lewy body trial plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPR1FkeERsNWtFMnpwYkZnN3p2V3JHSWZCZks4UDdkTFBPUzZkVWVSd3lhU0xHRHZrdEtEYkFnOW9xb21BQ1BTTmYxb1JnSGdtbEg4Um5yMDJaWUQ5RjBzMXlnbHhseWF1X29tR2NSS1RXWEFLbXdxNEV4RENZTHd6MUtvdXAza01XWWZWYlZpOUFSc2ZHVkQteU9NTklWNXdYRUFfM1JuZC1RQng2Vjl0VVJpTnp2d0llcEg2azRKZjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lewy body dementia MRI data spotlight CervoMed's planned Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNN1ZkM3JKaUVGN2xSOGwwbDN3cEVrbXBzTmdNVDhIWW1uT2VzaW0tQUpmRjlHVDd4MEdDdGdfZ1d0ZVYwTy16Ykt0WENJTjJBcW91ZV9XS1hTcGFtYkxNam1ld0hPUFVTenlnalNLb2RHbHdfbU1wMkdMQnJPaVNzakpqOW42STlmdWpzbGM1Zi1weTdXLXI4U0psUVBYaDcxNUNPU0dFeEtoSV9iTHJKd2VPMDNncWw5Tzg2OEQwNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With no approved DLB drugs, CervoMed maps out a Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdU5fUkotY0xHUXgwSHNla2RoQm5aMlF4UEwwMi14Yks0NS1TWlVmQzRvSUZkWnVaTmkyNy15cFdmczVNdWN6TzRBV0UxY3Z3WkFPZWF5VVg4dE9pS2dzcW1wLVk3ZjF4cW5RSktBV29CalFaVHdYcGp0OGdOVGh2aWNJVG5KczdEZnY1clFmMXVsU1A1aGlpYV90WndlS0lTc2VaVy13RVhWdi15OWplTmRVc3NfaXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 49, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 30, "score": 58, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "liquidity", "label": "Balance sheet", "weight": 3.85, "count": 7}, {"event": "earnings", "label": "Earnings", "weight": 3.44, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 17, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.24, "latest_week": "2026-06-19", "one_week_move": 73.1, "four_week_move": 38.6, "twelve_week_move": 14.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.198571, "market_dynamics_buy_signal": false, "relative_strength": -46.374014, "fair_value_gap": -54.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.3715, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+73.1% over one week, +38.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "StocksToTrade", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 8}, {"label": "Balance sheet", "count": 7}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+73.1% over one week, +38.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "CervoMed (NASDAQ: CRVO) seeks $10M via 2.5M-share offering; patent allowance noted"}], "updated_at": "2026-06-22T20:02:24.119181+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}